Hyperliquid Strategies Inc Authorizes $30 Million Stock Repurchase Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Source: Newsfilter
- Repurchase Program Initiated: Hyperliquid Strategies Inc's Board has authorized a stock repurchase program of up to $30 million, set to last for 12 months, aimed at enhancing per-share value and boosting shareholder confidence.
- Maximizing Shareholder Value: CEO David Schamis emphasized the company's commitment to maximizing shareholder value through disciplined financial strategies, particularly by increasing exposure to HYPE tokens for capital efficiency.
- Market Operation Flexibility: The repurchase will occur through open market transactions, privately negotiated deals, or other means compliant with federal securities laws, with the timing, number, and value of shares to be determined flexibly by management based on market conditions.
- Future Uncertainty: Although the repurchase program is approved, the company does not guarantee the repurchase of a specific number of shares, and the program may be extended, suspended, or discontinued at any time, reflecting the high uncertainty in market and economic conditions.
Analyst Views on PURR
Wall Street analysts forecast PURR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PURR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 3.650
Low
Averages
High
Current: 3.650
Low
Averages
High
About PURR
Hyperliquid Strategies Inc is a digital asset treasury company. The Company is focused on accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. The Company’s subsidiary is Sonnet BioTherapeutics Holdings, Inc., which is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





